Education
About Us
Working with TipRanks
Follow Us
Nephros Inc (NEPH)
NASDAQ:NEPH
Top Page
Nephros
(NASDAQ:NEPH)
Select Model
Select Model
Rating:57Neutral
Price Target:
$3.00
▼(-40.12% Downside)
Action:ReiteratedDate:03/17/26
The score is primarily supported by improving fundamentals (profitability turnaround, strong gross margins, low leverage) and generally constructive earnings-call guidance, but is held back by weak technical trend/momentum and a high P/E with no dividend support.
Positive Factors
High Gross Margins
Consistently strong gross margins (~61–62%) reflect favorable product economics for Nephros's filtration devices and consumables. Durable product-level margins support reinvestment in R&D, services and go-to-market efforts, and provide a cushion against cost shocks over the medium term.
Recurring, Installed-Base Revenue
A programmatic model (>90% of revenue) with ~1,681 active sites creates predictable, repeatable demand from consumable replacements and service programs. This installed-base-driven revenue mix increases revenue visibility and customer retention, underpinning steady cashflows as the base grows.
Conservative Leverage and Liquidity
Low leverage, improved equity and a cash balance (~$5.4M) provide financial flexibility. A conservative balance sheet reduces refinancing and solvency risk, allowing the company to fund product, services and education initiatives and to absorb near-term turbulence while scaling.
Negative Factors
Historical Profitability Volatility
Despite a 2024–25 turnaround, the company’s multi-year history of losses and uneven cash generation weakens confidence in sustained profitability. Small absolute scale means adverse demand or one-off costs could quickly reverse earnings progress, challenging durability of margins.
Working Capital and Cash Flow Variability
Free cash flow volatility and a notable working-capital build reduced cash conversion in 2025. As Nephros scales, elevated receivables and inventory requirements can strain liquidity and limit reinvestment capacity unless working-capital efficiency improves and conversion stabilizes.
Structural Cost Headwinds
Sustained tariff exposure and rising R&D/SG&A create structural pressure on margins. If import tariffs persist or operating spend remains elevated to support growth, it could erode the benefit of high gross margins and delay establishment of reliably higher net margins.
Nephros (NEPH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$31.93M
Dividend YieldN/A
Average Volume (3M)75.62K
Price to Earnings (P/E)43.4
Beta (1Y)-0.46
Revenue Growth32.36%
EPS GrowthN/A
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.01
Shares Outstanding10,644,268
10 Day Avg. Volume107,933
30 Day Avg. Volume75,620
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)5.08
Price to Sales (P/S)2.76
P/FCF Ratio31.48
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue1.47
Enterprise Value/Gross Profit2.40
Enterprise Value/Ebitda21.42
Forecast
1Y Price Target
$8.00Price Target Upside59.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.06
Revenue Forecast (FY)$20.78M
Nephros Business Overview & Revenue Model
Company DescriptionNephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
How the Company Makes MoneyNephros makes money primarily by selling point-of-use and related water filtration products and associated replacement filters/consumables used to maintain performance over time. Revenue is generated from (1) product sales of filtration devices and systems installed in facilities and (2) recurring sales of replacement cartridges/filters and related consumables required on a scheduled basis, creating an ongoing, installed-base-driven revenue stream after initial deployment. The company also sells into institutional customers (such as hospitals and other facilities managing water safety), where adoption can be supported by infection-prevention and water-management needs; however, specific customer concentration, pricing terms, and partnership details are null.
Nephros Earnings Call Summary
Earnings Call Date:Mar 12, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call conveyed a largely positive operational and financial story: solid top-line growth (+33% FY), return to full-year profitability (~$1.2M), improved full-year adjusted EBITDA and positive operating cash flow, expansion of product/service/education initiatives, and an increased active site base. Near-term headwinds were highlighted—most notably Q4 margin compression (58% vs 64% prior-year quarter) driven by import tariffs, higher quarterly SG&A and R&D spend, one-time Q4 expenses, and working capital build that pressured quarterly EBITDA and net income. On balance, the company appears to be scaling with improving annual profitability and cash generation, while managing near-term cost and tariff-related margin challenges.Q4-2025 Updates
Positive Updates
Strong Revenue Growth
Full-year 2025 revenue of $18.8M, up 33% from $14.2M in 2024; Q4 2025 revenue of $4.7M, up 22% year-over-year, driven by higher programmatic reorder activity and new active sites.
Returned to Profitability
Net income for FY2025 of approximately $1.2M versus $0.1M in 2024 (material improvement), marking the company's second consecutive year of profitability.
Improved Full-Year Adjusted EBITDA and Operating Cash Flow
Adjusted EBITDA for FY2025 was a positive $1.6M versus $0.548M in 2024; net cash provided by operating activities was $1.6M in 2025 compared with net cash used of ~$0.5M in 2024, reflecting stronger cash generation.
Growing and Sticky Customer Base (Programmatic Revenue)
Active customer sites increased to ~1,681 from ~1,500 at year-end 2024 (≈+12%); management reported programmatic sales accounted for over 90% of revenue, supporting recurring revenue visibility.
Strong Balance Sheet and Financial Discipline
Year-end cash of $5.4M (up from $3.8M a year earlier), and the company remains debt-free, supporting liquidity and operational flexibility.
Product, Services and Education Expansion
Launched expanded product applications (ice machines, drinking fountains, bottle fillers, sterile processing), rolled out Services (installation/replacement programs) and launched the Nephros Water Institute; education efforts reached 1,000+ attendees to drive long-term demand.
Negative Updates
Quarterly Margin Pressure
Gross margin declined to 58% in Q4 2025 from 64% in Q4 2024 (down 6 percentage points), despite full-year gross margin holding at 62% year-over-year.
Tariff-Related Cost Headwinds and Uncertainty
Management cited a 15% tariff on goods imported from Italy beginning April 2025 (reduced to 10% on Feb 22, 2026) as a primary driver of margin erosion and noted ongoing uncertainty in U.S. tariff policy.
Higher Operating Expenses in the Quarter
R&D increased to $1.3M in 2025 from $0.9M in 2024 (≈+44% year-over-year); Q4 R&D rose to $0.4M vs $0.3M prior year. SG&A rose to $9.0M in 2025 from $7.7M in 2024 (+17%), with Q4 SG&A up ~24% driven by bonuses, commissions and some one-time product/market analysis expenses.
Weaker Q4 Profitability and EBITDA vs Prior Year Quarter
Q4 2025 net income was approximately $0.1M versus $0.3M in Q4 2024 (down ~67%); Q4 adjusted EBITDA was $131K compared with $481K in the prior-year quarter, reflecting the margin and expense mix impact late in the year.
Working Capital Build
FY2025 operating cash included increases in accounts receivable (~$0.6M) and inventory (~$0.7M), which absorbed cash and may indicate near-term working capital pressure as the business scales.
Reliance on Programmatic/Concentrated Revenue
While programmatic revenue (>90%) provides recurring revenue, heavy reliance on a single revenue pattern and a still-developing non-healthcare commercial pipeline could concentrate exposure if reorder rates or site growth slow.
Company Guidance
Management framed 2026 as a continued, multi‑year growth story built on three pillars—products, services and education—with emphasis on expanding recurring programmatic revenue (over 90% of sales in Q4 and for FY2025) as active sites rise (≈1,681 at year‑end). They pointed to 2025 results that underpin the outlook: revenue +33% to $18.8M (Q4 $4.7M, +22% YoY), net income ≈$1.2M, adjusted EBITDA $1.6M for the year ($131k in Q4), gross margin 62% for FY2025 (58% in Q4), $5.4M cash and no debt, while flagging cost pressures from tariffs (15% on Italian imports since April 2025, reduced to 10% Feb 22, 2026) and higher R&D ($1.3M) and SG&A ($9.0M).Nephros Financial Statement Overview
Summary
Financials reflect a real turnaround with strong gross margins (~61–62%), improved profitability in 2024–2025, and conservative leverage; however, net margins are still modest (~6% in 2025) and earnings/free-cash-flow history remains volatile, limiting confidence in durability.Income Statement
Profitability has improved meaningfully versus prior years, with the company turning profitable in 2024 and expanding further in 2025 (net income of ~$1.2M on ~$18.8M revenue). Gross margin is consistently strong (~61–62% in 2024–2025), showing good product economics. The main weakness is that bottom-line margins are still modest (~6% net margin in 2025) and the historical track record includes multiple years of sizable losses (2020–2023), indicating earnings durability is not yet fully proven.62
Positive
Balance Sheet
Leverage looks conservative, with low debt relative to equity (debt-to-equity ~0.10 in 2025, improved from ~0.16 in 2024), which provides financial flexibility. Equity has grown versus 2022–2024 and returns on equity improved sharply in 2025 (~11.7%) after being near breakeven in 2024. The key risk is scale: absolute asset and equity levels are modest, and the business has historically experienced meaningful swings in profitability that could pressure the balance sheet if losses re-emerge.78
Positive
Cash Flow
Cash generation rebounded strongly in 2025 (operating cash flow and free cash flow both ~$1.6M, and free cash flow roughly matched net income), a notable improvement from negative operating and free cash flow in 2024. However, free cash flow declined sharply year-over-year in 2025 (about -39.5%), and the company’s cash flow profile has been volatile across 2020–2024, which reduces confidence in consistency despite the latest year’s positive result.55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 18.79M | 14.16M | 14.24M | 9.97M | 10.22M |
| Gross Profit | 11.48M | 8.72M | 8.40M | 4.73M | 5.63M |
| EBITDA | 1.29M | 227.00K | -1.36M | -3.69M | -2.49M |
| Net Income | 1.19M | 74.00K | -1.57M | -7.38M | -4.11M |
Balance Sheet | |||||
| Total Assets | 13.64M | 11.21M | 11.86M | 11.00M | 17.65M |
| Cash, Cash Equivalents and Short-Term Investments | 5.40M | 3.76M | 4.31M | 3.63M | 6.97M |
| Total Debt | 1.06M | 1.41M | 1.84M | 1.09M | 1.00M |
| Total Liabilities | 3.44M | 2.63M | 3.50M | 2.12M | 2.90M |
| Stockholders Equity | 10.20M | 8.59M | 8.36M | 5.59M | 11.70M |
Cash Flow | |||||
| Free Cash Flow | 1.65M | -547.00K | 752.00K | -3.37M | -1.45M |
| Operating Cash Flow | 1.65M | -492.00K | 827.00K | -3.23M | -1.42M |
| Investing Cash Flow | 0.00 | -50.00K | -75.00K | -137.00K | -85.00K |
| Financing Cash Flow | -5.00K | -5.00K | -79.00K | 34.00K | 237.00K |
Nephros Technical Analysis
Negative
5.01
Price Trends
4.18
Negative
4.63
Negative
4.36
Negative
Market Momentum
-0.23
Positive
31.12
Neutral
7.61
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEPH, the sentiment is Negative. The current price of 5.01 is above the 20-day moving average (MA) of 3.80, above the 50-day MA of 4.18, and above the 200-day MA of 4.36, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 31.12 is Neutral, neither overbought nor oversold. The STOCH value of 7.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NEPH.
Nephros Risk Analysis
Nephros disclosed 25 risk factors in its most recent earnings report. Nephros reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nephros Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $31.93M | 43.37 | 12.22% | ― | 32.36% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $21.00M | 16.98 | -8.13% | ― | -0.95% | 58.17% | |
47 Neutral | $21.78M | -26.08 | -388.56% | ― | -10.60% | -271.93% | |
42 Neutral | $22.24M | -8.10 | -164.78% | ― | 0.59% | -39.76% | |
41 Neutral | $34.51M | -0.61 | -764.17% | ― | 63.53% | 12.49% |
* Healthcare Sector Average
NEPH
Nephros
3.00
1.48
97.37%
HBIO
Harvard Bioscience
4.87
-1.87
-27.70%
RVP
Retractable Technologies
0.70
-0.02
-3.04%
MLSS
Milestone Scientific
0.28
-0.65
-69.61%
FEMY
Femasys
0.58
-0.96
-62.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.